Black Diamond Therapeutics Earning Date (BDTX)

USA |NASDAQ |USD

BDTX Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Aug 10, 2022 Jun 2022 - - $-0.95
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Aug 10, 2022 Jun 2022 - - $0.00

Black Diamond Therapeutics's next earnings date is Wednesday, Aug 10, 2022 for the fiscal quarter ending Jun 2022.

BDTX Earnings Date & History Chart

BDTX Earnings & Revenue Forecast

BDTX Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 7 $-3.84 $-4.61 $-3.18

BDTX Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2022 0 / 0 $-3.84 $-3.84 $-3.73

BDTX Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 7 $0.00 $0.00 $0.00

BDTX Earnings Date & Revenue History

BDTX Earnings History

|
Show More
Show More

BDTX Revenue History

|
Show More
Show More

Black Diamond Therapeutics Next Earnings Date & Report

BDTX Next Earnings Date & Report Preview: Jun 2022 (FQ)

BDTX's next earnings date is Wednesday, Aug 10, 2022 for the fiscal quarter ending Jun 30, 2022.

Black Diamond Therapeutics Previous Earnings Dates & Reports

BDTX Previous Earnings Date & Report Recap: Mar 2022 (FQ)

Black Diamond Therapeutics's previous earnings date was May 5, 2022 for its fiscal quarter ended Mar 31, 2022.

BDTX Previous Earnings Date & Report Recap: Dec 2021 (FY)

Black Diamond Therapeutics's previous annual earnings date was Mar 17, 2022 for its fiscal year ended Dec 31, 2021.

BDTX's earnings per share (EPS) was $-3.47, beating the consensus analysts forecast of $-3.78 by -8.20% , and lower than the previous year's EPS (Dec 2020) by 69.27%.

Revenues were $0.00.

The company reported a net income of $-125.60K.

Black Diamond Therapeutics reported a free cash flow of $-102.86M for its fiscal year, compared to $-52.29M a year ago.